Kura Oncology, INC Schedule 13G passive stakes

Montanova Capital, Averill Master Fund, and Aaron Cowen have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Kura Oncology, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 3,736,000 shares, representing 4.23% of Kura Oncology, Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has disclosed beneficial ownership of over 4.4 million shares, representing 5.01% of Kura Oncology Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Kura Oncology Inc. following an internal realignment.

State Street Corporation has reported a 5.7% beneficial ownership stake in Kura Oncology Inc. common stock as of December 31, 2025.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5.37% in Kura Oncology, Inc., holding 4,672,000 shares as of September 30, 2025.

Biotechnology Value Fund and its affiliates report a 9.99% passive stake in Kura Oncology, Inc., holding 8,677,018 common shares.

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 7.14% in Kura Oncology, Inc., holding 6.2 million shares.

EcoR1 Capital, LLC and affiliated entities reported a passive beneficial ownership of 4.8% in Kura Oncology, Inc. common stock as of June 30, 2025.

RA Capital Management, along with its affiliates and key personnel, has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 4.9% in Kura Oncology, Inc., indicating a reduction below the 5% reporting threshold.

Armistice Capital, LLC and its managing member Steven Boyd have reported a beneficial ownership of 7.59% in Kura Oncology, Inc., totaling 6,572,000 shares of common stock.

Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an amended Schedule 13G, revealing a combined passive beneficial ownership of 9.4% in Kura Oncology, Inc.'s common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.8% beneficial ownership stake in Kura Oncology Inc. as of March 31, 2025.

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 7.46% in Kura Oncology, Inc., totaling 5.8 million shares of common stock as of December 31, 2024.

Paradigm BioCapital Advisors LP and its affiliated entities have reported the complete divestiture of their beneficial ownership in Kura Oncology, Inc. as of December 31, 2024.

Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an amended Schedule 13G, reporting a combined passive beneficial ownership of 6.7% in Kura Oncology, Inc. as of December 31, 2024.

Deerfield Mgmt, L.P. and its affiliated entities have filed an amended Schedule 13G, indicating they no longer hold any beneficial ownership in Kura Oncology, Inc. as of December 31, 2024.

A group of investment entities led by Mark N. Lampert, including Biotechnology Value Fund L.P., has reported a 7.5% passive beneficial ownership stake in Kura Oncology, Inc. as of January 27, 2025.

A group of investment entities led by Biotechnology Value Fund, including Mark N. Lampert, has filed an amendment to their Schedule 13G, disclosing a collective beneficial ownership of 4.3% in Kura Oncology, Inc. as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, reporting a beneficial ownership of 10.2% of Kura Oncology, Inc.'s common stock as of December 31, 2024.